Corbus Pharmaceuticals Holdings, Inc. Share Price
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.085 USD | +0.06% |
|
+1.17% | +11.61% |
| Market Cap | 168M 148M 138M 127M 237M 16.08B 241M 1.63B 639M 7.98B 632M 618M 27.55B | P/E 2026 * |
-1.95x | P/E 2027 * | -1.72x |
|---|---|---|---|---|---|
| Enterprise Value | 168M 148M 138M 127M 237M 16.08B 241M 1.63B 639M 7.98B 632M 618M 27.55B | EV / Sales 2026 * |
151x | EV / Sales 2027 * | 70.1x |
| Free-Float |
98.92% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corbus Pharmaceuticals Holdings, Inc.
| 1 day | +0.06% | ||
| 1 week | +1.17% | ||
| Current month | -3.14% | ||
| 1 month | +3.95% | ||
| 3 months | -7.48% | ||
| 6 months | +4.43% | ||
| Current year | +11.61% |
| 1 week | 8.73 |  | 9.54 |
| 1 month | 8.5 | | 9.88 |
| Current year | 7.12 | | 12.88 |
| 1 year | 7.12 | | 20.56 |
| 3 years | 3.03 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 323.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 10/04/2014 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 10/04/2014 |
Leonardo Nicacio
CTO | Chief Tech/Sci/R&D Officer | 48 | 05/07/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 10/04/2014 |
John Jenkins
BRD | Director/Board Member | 68 | 04/06/2018 |
Rachelle Jacques
CHM | Chairman | 54 | 14/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/06/26 | Sell | Director | -2,412 | 0.0130% | ||
| 10/06/26 | Sell | Director | -4,800 | 0.0259% | ||
| 10/06/26 | Sell | Director | -2,026 | 0.0109% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.06% | +1.17% | -5.27% | +37.65% | 168M | |
| -0.78% | +1.00% | +48.91% | +67.61% | 55.01B | |
| -1.32% | -2.71% | +34.27% | +77.57% | 54.24B | |
| +1.49% | +0.13% | -18.03% | -13.94% | 23.38B | |
| -0.57% | -4.13% | +2.34% | +387.73% | 22.57B | |
| +2.33% | +1.65% | +17.50% | -10.48% | 20.19B | |
| -0.20% | -0.68% | +29.38% | -31.90% | 17.86B | |
| -2.10% | -3.75% | +26.23% | +558.64% | 15.5B | |
| -6.69% | -5.11% | +169.13% | +304.89% | 14.2B | |
| +1.25% | +0.69% | +27.30% | +184.69% | 14.2B | |
| Average | -0.66% | -0.48% | +33.18% | +156.25% | 23.73B | |
| Weighted average by Cap. | -0.67% | -0.52% | +34.78% | +131.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 975K 908K 835K 1.57M 106M 1.59M 10.77M 4.22M 52.64M 4.17M 4.08M 182M | 2.4M 2.11M 1.96M 1.8M 3.38M 229M 3.44M 23.27M 9.11M 114M 9.01M 8.82M 393M |
| Net income | -97.64M -85.69M -79.79M -73.39M -138M -9.33B -140M -947M -371M -4.63B -367M -359M -15.98B | -123M -108M -100M -92.25M -173M -11.73B -176M -1.19B -466M -5.82B -461M -451M -20.09B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/07/26 | US$9.085 | +0.06% | 155,183 |
| 27/07/26 | US$9.080 | -0.98% | 363,251 |
| 24/07/26 | US$9.170 | -1.61% | 172,705 |
| 23/07/26 | US$9.320 | +5.43% | 639,811 |
| 22/07/26 | US$8.840 | -1.56% | 154,538 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRBP Stock
Select your edition
All financial news and data tailored to specific country editions
